The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics (PK) and pharmacodynamics (PD) of rituximab administered by faster infusion in patients with previously untreated diffuse large B-cell (DLBCL) or follicular lymphoma (FL).
Michael Brewster
Employment or Leadership Position - Roche
Stock Ownership - Roche
Deborah Hurst
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Akiko Chai
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Edward James Lee
Research Funding - Genentech
Gargi H. Upadhyaya
Research Funding - Genentech
Shaker R. Dakhil
Research Funding - Genentech